Pacer Advisors
FDMT icon

Pacer Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Pacer Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Buy
+747
New +$7.28K ﹤0.01% 2348
2024
Q3 		– Sell
-544
Closed -$11.4K – 2609
2024
Q2 		$11.4K Sell
544
-185
-25% -$4.64K ﹤0.01% 3525
2024
Q1 		$23.2K Buy
+729
New +$18.6K ﹤0.01% 3418

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Pacer Advisors's FDMT Position: Q2 2026 in Review

Pacer Advisors opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 747 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #2348 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in FDMT as recently as Q2 2024.

Pacer Advisors first reported a position in FDMT in Q1 2024 and has held it in 3 quarters since. The position peaked at $23.2K in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Pacer Advisors held 747 shares of 4D Molecular Therapeutics worth $10K as of Q2 2026.
  • 4D Molecular Therapeutics was a new Pacer Advisors position in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2348 holding.
  • Pacer Advisors first reported a position in 4D Molecular Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Pacer Advisors's 4D Molecular Therapeutics position peaked at $23.2K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.